Advertisement

Journal of Bone and Mineral Metabolism

, Volume 37, Issue 3, pp 563–572 | Cite as

Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea

  • Dong Won Byun
  • Seong-Hwan Moon
  • Tak Kim
  • Hae-Hyeog Lee
  • Hyoung Moo Park
  • Moo-Il Kang
  • Yong-Chan Ha
  • Ho-Yeon Chung
  • Byung-Koo Yoon
  • Tae-Young Kim
  • Soo Uk Chae
  • Chan Soo Shin
  • Kyu-Hyun Yang
  • Jae Hyup Lee
  • Jae Suk Chang
  • Sung Hoon Kim
  • In Joo Kim
  • Jung-Min Koh
  • Jung Hwa Jung
  • Kyong Wook Yi
  • Jeong Joon Yoo
  • Dong Jin Chung
  • Young-Kyun Lee
  • Hyun-Koo Yoon
  • Seongbin Hong
  • Deog-Yoon Kim
  • Ki Hyun Baek
  • Hyun-Joo Kim
  • Young-Joo Kim
  • Seongsik Kang
  • Yong-Ki MinEmail author
Original Article

Abstract

Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.

Keywords

Postmenopausal osteoporosis Treatment satisfaction Medication adherence Quality of life Gastrointestinal events 

Notes

Acknowledgements

This research was sponsored by Pfizer.

Compliance with ethical standards

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

All authors have no conflicts of interest.

Supplementary material

774_2018_956_MOESM1_ESM.docx (43 kb)
Supplementary material 1 (DOCX 43 kb)

References

  1. 1.
    Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM (2015) The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging 10:583–591.  https://doi.org/10.2147/CIA.S54614 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Choi YJ, Oh HJ, Kim DJ, Lee Y, Chung YS (2012) The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: the Korea National Health and Nutrition Examination Survey 2008–2009. J Bone Miner Res 27:1879–1886.  https://doi.org/10.1002/jbmr.1635 CrossRefGoogle Scholar
  3. 3.
    Anonymous (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650Google Scholar
  4. 4.
    Wactawski-Wende J (2001) Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol 6:197–208.  https://doi.org/10.1902/annals.2001.6.1.197 CrossRefPubMedGoogle Scholar
  5. 5.
    Watts NB, Manson JE (2017) Osteoporosis and fracture risk evaluation and management: shared decision making in clinical practice. JAMA 317:253–254.  https://doi.org/10.1001/jama.2016.19087 CrossRefPubMedGoogle Scholar
  6. 6.
    Yoon HK, Park C, Jang S, Jang S, Lee YK, Ha YC (2011) Incidence and mortality following hip fracture in Korea. J Korean Med Sci 26:1087–1092.  https://doi.org/10.3346/jkms.2011.26.8.1087 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Woo C, Gao G, Wade S, Hochberg MC (2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26:1003–1009.  https://doi.org/10.1185/03007991003633603 CrossRefPubMedGoogle Scholar
  8. 8.
    Patrick ARBM, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH (2010) The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 95:3251–3259CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chapurlat R, Delmas PD (2004) Treatment of postmenopausal osteoporosis. Rev Prat (Traitement de l’osteoporose post-menopausique) 54:2120–2126Google Scholar
  10. 10.
    Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H, American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive A (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243–1251CrossRefPubMedGoogle Scholar
  11. 11.
    Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D (2007) Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 25:105–113.  https://doi.org/10.1007/s00774-006-0735-7 CrossRefPubMedGoogle Scholar
  12. 12.
    Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D (2016) Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother 17:1141–1152.  https://doi.org/10.1080/14656566.2016.1176147 CrossRefPubMedGoogle Scholar
  13. 13.
    Valderas JM, Kotzeva A, Espallargues M, Guyatt G, Ferrans CE, Halyard MY, Revicki DA, Symonds T, Parada A, Alonso J (2008) The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res 17:179–193.  https://doi.org/10.1007/s11136-007-9295-0 CrossRefPubMedGoogle Scholar
  14. 14.
    Alan Brookhart JA, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251–256CrossRefPubMedGoogle Scholar
  15. 15.
    Sweileh WM, Ihbesheh MS, Jarar IS, Taha AS, Sawalha AF, Zyoud SH, Jamous RM, Morisky DE (2011) Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 21:301–305.  https://doi.org/10.1016/j.yebeh.2011.04.011 CrossRefPubMedGoogle Scholar
  16. 16.
    Zyoud SH, Al-Jabi SW, Sweileh WM, Morisky DE (2013) Relationship of treatment satisfaction to medication adherence: findings from a cross-sectional survey among hypertensive patients in Palestine. Health Qual Life Outcomes 11:191.  https://doi.org/10.1186/1477-7525-11-191 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Miyakoshi N, Kudo D, Hongo M, Kasukawa Y, Ishikawa Y, Shimada Y (2017) Comparison of spinal alignment, muscular strength, and quality of life between women with postmenopausal osteoporosis and healthy volunteers. Osteoporos Int.  https://doi.org/10.1007/s00198-017-4184-z CrossRefPubMedGoogle Scholar
  18. 18.
    Madureira MM, Ciconelli RM, Pereira RM (2012) Quality of life measurements in patients with osteoporosis and fractures. Clinics (Sao Paulo) 67:1315–1320CrossRefGoogle Scholar
  19. 19.
    Baczyk G, Samborski W, Jaracz K (2016) Evaluation of the quality of life of postmenopausal osteoporotic and osteopenic women with or without fractures. Arch Med Sci 12:819–827.  https://doi.org/10.5114/aoms.2015.55012 CrossRefPubMedGoogle Scholar
  20. 20.
    Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213–221.  https://doi.org/10.1007/s00296-009-0940-5 CrossRefPubMedGoogle Scholar
  21. 21.
    Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–1644.  https://doi.org/10.1007/s00198-006-0166-2 CrossRefPubMedGoogle Scholar
  22. 22.
    Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12.  https://doi.org/10.1186/1477-7525-2-12 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Reynolds K, Viswanathan HN, Muntner P, Harrison TN, Cheetham TC, Hsu JW, Gold DT, Silverman S, Grauer A, Morisky DE, O’Malley CD (2014) Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates. Qual Life Res 23:2109–2120.  https://doi.org/10.1007/s11136-014-0662-3 CrossRefPubMedGoogle Scholar
  24. 24.
    Lee YK, Nam HS, Chuang LH, Kim KY, Yang HK, Kwon IS, Kind P, Kweon SS, Kim YT (2009) South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. Value Health 12:1187–1193.  https://doi.org/10.1111/j.1524-4733.2009.00579.x CrossRefPubMedGoogle Scholar
  25. 25.
    Voko Z, Gaspar K, Inotai A, Horvath C, Bors K, Speer G, Kalo Z (2017) Osteoporotic fractures may impair life as much as the complications of diabetes. J Eval Clin Pract 23:1375–1380.  https://doi.org/10.1111/jep.12800 CrossRefPubMedGoogle Scholar
  26. 26.
    Kuo SZ, Haftek M, Lai JC (2017) Factors associated with medication non-adherence in patients with end-stage liver disease. Dig Dis Sci 62:543–549.  https://doi.org/10.1007/s10620-016-4391-z CrossRefPubMedGoogle Scholar
  27. 27.
    Espallargues M, Valderas JM, Alonso J (2000) Provision of feedback on perceived health status to health care professionals: a systematic review of its impact. Med Care 38:175–186CrossRefPubMedGoogle Scholar
  28. 28.
    Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguelez R, Sacristan J, Marin F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256CrossRefPubMedGoogle Scholar
  29. 29.
    Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2010) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporos Int 23:733–741Google Scholar
  30. 30.
    Mulligan R, Sobel S (2005) Osteoporosis: diagnostic testing, interpretation, and correlations with oral health—implications for dentistry. Dent Clin N Am 49:463–484.  https://doi.org/10.1016/j.cden.2004.10.005 CrossRefPubMedGoogle Scholar
  31. 31.
    Warriner AH, Curtis JR (2009) Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 21:356–362.  https://doi.org/10.1097/BOR.0b013e32832c6aa4 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968.  https://doi.org/10.1007/s00198-003-1502-4 CrossRefPubMedGoogle Scholar
  33. 33.
    Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL (2009) Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 122:961 e7–13.  https://doi.org/10.1016/j.amjmed.2008.12.021 CrossRefPubMedGoogle Scholar
  34. 34.
    Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008.  https://doi.org/10.1007/s00198-004-1652-z CrossRefPubMedGoogle Scholar
  35. 35.
    Robitaille J, Yoon PW, Moore CA, Liu T, Irizarry-Delacruz M, Looker AC, Khoury MJ (2008) Prevalence, family history, and prevention of reported osteoporosis in U.S. women. Am J Prev Med 35:47–54.  https://doi.org/10.1016/j.amepre.2008.03.027 CrossRefPubMedGoogle Scholar
  36. 36.
    Hong SM, Choi WH (2011) Osteoporosis and decrease in bone mineral density have associated with the reduced quality of life. Osteoporosis 9:175–179Google Scholar
  37. 37.
    Dhillon V, Hurst N, Hannan J, Nuki G (2005) Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture. Osteoporos Int 16:483–489.  https://doi.org/10.1007/s00198-004-1705-3 CrossRefPubMedGoogle Scholar
  38. 38.
    Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, Osteoporosis Methodology G, The Osteoporosis Research Advisory G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523.  https://doi.org/10.1210/er.2001-3002 CrossRefPubMedGoogle Scholar
  39. 39.
    Rosen CJ (2005) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595–603.  https://doi.org/10.1056/NEJMcp043801 CrossRefPubMedGoogle Scholar
  40. 40.
    Eekman DA, Vis M, Bultink IE, Derikx HJ, Dijkmans BA, Lems WF (2009) Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates. BMC Musculoskelet Disord 10:86.  https://doi.org/10.1186/1471-2474-10-86 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, Group FR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938.  https://doi.org/10.1001/jama.296.24.2927 CrossRefPubMedGoogle Scholar
  42. 42.
    Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cotté FE (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 10:26.  https://doi.org/10.1186/1472-6874-10-26 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Dong Won Byun
    • 1
  • Seong-Hwan Moon
    • 2
  • Tak Kim
    • 3
  • Hae-Hyeog Lee
    • 4
  • Hyoung Moo Park
    • 5
  • Moo-Il Kang
    • 6
  • Yong-Chan Ha
    • 7
  • Ho-Yeon Chung
    • 8
  • Byung-Koo Yoon
    • 9
  • Tae-Young Kim
    • 10
  • Soo Uk Chae
    • 11
  • Chan Soo Shin
    • 12
  • Kyu-Hyun Yang
    • 13
  • Jae Hyup Lee
    • 14
  • Jae Suk Chang
    • 15
  • Sung Hoon Kim
    • 16
  • In Joo Kim
    • 17
  • Jung-Min Koh
    • 18
  • Jung Hwa Jung
    • 19
  • Kyong Wook Yi
    • 20
  • Jeong Joon Yoo
    • 21
  • Dong Jin Chung
    • 22
  • Young-Kyun Lee
    • 23
  • Hyun-Koo Yoon
    • 24
  • Seongbin Hong
    • 25
  • Deog-Yoon Kim
    • 26
  • Ki Hyun Baek
    • 27
  • Hyun-Joo Kim
    • 28
  • Young-Joo Kim
    • 28
  • Seongsik Kang
    • 28
  • Yong-Ki Min
    • 29
    Email author
  1. 1.Department of Endocrinology, Internal MedicineSoon Chun Hyang University HospitalSeoulSouth Korea
  2. 2.Department of Orthopedic Surgery, Severance HospitalYonsei University Health SystemSeoulSouth Korea
  3. 3.Department of Obstetrics and Gynecology, Korea University Anam HospitalKorea University College of MedicineSeoulSouth Korea
  4. 4.Department of Obstetrics and GynecologySoonchunhyang University Bucheon HospitalBucheonSouth Korea
  5. 5.Department of Obstetrics and GynecologyChung-Ang University HospitalSeoulSouth Korea
  6. 6.Division of Endocrinology and Metabolism, Department of Internal MedicineSeoul St. Mary’s HospitalSeoulSouth Korea
  7. 7.Department of Orthopedic SurgeryChung-Ang University HospitalSeoulSouth Korea
  8. 8.Department of Endocrinology and MetabolismKyung Hee University, School of MedicineSeoulSouth Korea
  9. 9.Department of Obstetrics and Gynecology, Samsung Medical CenterSungkyunkwan UniversitySeoulSouth Korea
  10. 10.Department of Orthopedic Surgery, Konkuk University Medical CenterKonkuk University School of MedicineSeoulSouth Korea
  11. 11.Department of Orthopedic SurgeryGunsan Medical Center of Wonkwang University HospitalGunsanSouth Korea
  12. 12.Department of Internal MedicineSeoul National University HospitalSeoulSouth Korea
  13. 13.Department of Orthopedic Surgery, Gangnam Severance HospitalYonsei University College of MedicineSeoulSouth Korea
  14. 14.Department of Orthopedic SurgerySeoul National University College of Medicine, SMG-SNU Boramae Medical CenterSeoulSouth Korea
  15. 15.Department of Orthopedic Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  16. 16.Department of Obstetrics and Gynecology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  17. 17.Division of Endocrinology and Metabolism, Department of Internal MedicinePusan National University HospitalBusanSouth Korea
  18. 18.Division of Endocrinology and Metabolism, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  19. 19.Department of Internal Medicine, Gyeongsang National University HospitalGyeongsang National University School of MedicineJinjuSouth Korea
  20. 20.Department of Obstetrics and Gynecology, Korea University College of MedicineKorea University Ansan HospitalAnsanSouth Korea
  21. 21.Department of Orthopedic Surgery, Seoul National University College of MedicineSeoul National University HospitalSeoulSouth Korea
  22. 22.Department of Internal MedicineChonnam National University Medical SchoolGwangjuSouth Korea
  23. 23.Department of Orthopedic SurgerySeoul National University Bundang HospitalSeongnamSouth Korea
  24. 24.Division of Endocrinology and Metabolism, Department of Medicine, Cheil General Hospital and Women’s Healthcare CenterDankook UniversitySeoulSouth Korea
  25. 25.Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University HospitalInha University School of MedicineIncheonSouth Korea
  26. 26.Department of Nuclear MedicineKyung Hee University, School of MedicineSeoulSouth Korea
  27. 27.Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  28. 28.Pfizer Pharmaceuticals Korea LimitedSeoulRepublic of Korea
  29. 29.Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations